Endocrine Dysfunction in Diamond-Blackfan Anemia (DBA): A Report from the DBA Registry (DBAR) by Lahoti, A. et al.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2016
Endocrine Dysfunction in Diamond-Blackfan
Anemia (DBA): A Report from the DBA Registry
(DBAR)
A. Lahoti
Northwell Health
Y. T. Harris
Zucker School of Medicine at Hofstra/Northwell
P. W. Speiser
Zucker School of Medicine at Hofstra/Northwell
E. Atsidaftos
Northwell Health
J. M. Lipton
Zucker School of Medicine at Hofstra/Northwell
See next page for additional authors
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Pediatrics Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.
Recommended Citation
Lahoti A, Harris Y, Speiser P, Atsidaftos E, Lipton J, Vlachos A. Endocrine Dysfunction in Diamond-Blackfan Anemia (DBA): A
Report from the DBA Registry (DBAR). . 2016 Jan 01; 63(2):Article 2755 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/2755. Free full text article.
Authors
A. Lahoti, Y. T. Harris, P. W. Speiser, E. Atsidaftos, J. M. Lipton, and A. Vlachos
This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/2755
Endocrine Dysfunction in Diamond Blackfan Anemia (DBA): A 
Report from the DBA Registry (DBAR)
Amit Lahoti, MBBS1,2, Yael T Harris, MD, PhD2,3, Phyllis W Speiser, MD1,2,4, Evangelia 
Atsidaftos, MA, CCRP4, Jeffrey M Lipton, MD, PhD2,4,5, and Adrianna Vlachos, MD2,4,5
1Division of Endocrinology, Cohen Children’s Medical Center (CCMC), New Hyde Park, NY
2Hofstra North Shore-LIJ School of Medicine, Hempstead, NY
3Internal Medicine-Endocrinology, North Shore LIJ Health System (NSLIJHS), Manhasset, NY
4Feinstein Institute for Medical Research (FIMR); Manhasset, NY
5Division of Hematology/Oncology and Stem Cell Transplantation, CCMC, New Hyde Park, NY
Abstract
Objective—Diamond Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome. 
The mainstays of treatment involve chronic red cell transfusions, long-term glucocorticoid therapy, 
and stem cell transplantation. Systematic data concerning endocrine function in DBA are limited. 
We studied patients in the DBA Registry (DBAR) of North America to assess the prevalence of 
various endocrinopathies.
Study design—In a pilot study, retrospective data were collected for 12 patients with DBA. 
Subsequently, patients with DBA aged 1–39 years were recruited prospectively. Combined, 57 
patients were studied; 38 chronically transfused, 12 glucocorticoid-dependent and 7 in remission. 
Data were collected on anthropometric measurements, systematic screening tests of pituitary, 
thyroid, parathyroid, adrenal, pancreatic and gonadal function and ferritin levels. Descriptive 
statistics were tabulated and group differences assessed.
Results—Fifty-three percent of patients had ≥ 1 endocrine disorder, including adrenal 
insufficiency (32%), hypogonadism (29%), hypothyroidism (14%), growth hormone dysfunction 
(7%), diabetes mellitus (2%), and/or diabetes insipidus (2%). Ten of 33 patients with available 
heights had height SD <−2. Low 25(OH)D levels were present in 50%. A small proportion also 
had osteopenia, osteoporosis or hypercalciuria. Most with adrenal insufficiency were 
glucocorticoid-dependent; other endocrinopathies were more common in chronically transfused 
patients.
Conclusions—Endocrine dysfunction is common in DBA, as early as the teenage years. While 
prevalence is highest in transfused patients, patients taking glucocorticoids or in remission also 
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have endocrine dysfunction. Longitudinal studies are needed to better understand the etiology and 
true prevalence of these disorders.
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Hypogonadism; Growth; Vitamin D deficiency; Osteoporosis; Adrenal insufficiency; Iron overload
INTRODUCTION
Diamond Blackfan anemia (DBA), a rare inherited bone marrow failure syndrome affecting 
5–7 per million live births per year, is characterized by red cell aplasia, congenital anomalies 
and a predisposition to cancer. The most common mutations or deletions involve genes 
encoding ribosomal proteins[1–4].
The initial treatment is prednisone at a dose of 2 mg/kg/day commencing at 1 year of age, 
gradually weaned to ≤ 0.5 mg/kg/day. Although approximately 80% of patients respond to 
corticosteroids, only 40% have a sustained response without dose-limiting toxicity. Another 
40% are transfusion dependent, requiring packed red cells every 3–4 weeks. Interestingly, 
about 20% of patients enter remission, requiring neither glucocorticoids nor transfusions for 
≥6 months. Stem cell transplantation is considered in select patients[1].
Chronic glucocorticoid therapy predisposes patients to iatrogenic Cushing syndrome and 
adrenal insufficiency. Chronic blood transfusions place patients at risk for iron overload of 
liver, heart and endocrine organs. Growth failure, osteopenia, diabetes mellitus, and failure 
of the thyroid, parathyroids, adrenals, gonads and pituitary gland, may be related to therapy, 
and have been described in other hematologic diseases associated with iron overload and in 
aplastic anemia[5–8]. Endocrine dysfunction in DBA has only been described in case reports 
or small series[9–14]. Due to the rarity of DBA, there are no published systematic studies of 
endocrinopathies.
The DBA Registry (DBAR) of North America at the Feinstein Institute for Medical 
Research, North Shore-LIJ Health System (NSLIJHS) since 2000, provided an opportunity 
for a study of endocrine function in DBA[15]. Our aims were: (a) To study a cross-section of 
patients with DBA patients for glucose tolerance, pituitary, adrenal, thyroid, parathyroid and 
gonadal function; (b) To estimate the crude prevalence of hormone deficiencies in the DBA 
population; and (c) To compare the frequency of endocrine dysfunction in transfusion-
dependent group to those treated with glucocorticoids or in remission.
SUBJECTS AND METHODS
Subjects
We first performed a retrospective chart review of patients enrolled in DBAR evaluated in 
the divisions of medical and pediatric endocrinology of NSLIJHS between 1/1/04 and 
10/1/12. Twelve patients’ (aged 11–43) charts were reviewed. Subsequently subjects were 
recruited prospectively from 12/2012 to 4/2014. Inclusion criteria were: diagnosis of DBA 
according to DBAR criteria[1], aged 1–39 years, participating in DBAR, and a) receiving 
packed red cell transfusions every 3–4 weeks (at least 15 transfusions); or, b) in remission; 
Lahoti et al. Page 2
Pediatr Blood Cancer. Author manuscript; available in PMC 2016 April 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
or c) glucocorticoid dependent. Exclusion Criteria were: a) pregnancy or b) previous 
hematopoietic stem cell transplantation.
Study procedures
The protocol was approved by the NSLIJHS Institutional Review Board. Since the DBAR 
includes patients across North America, the principal investigator (PI) discussed consent via 
telephone, then sent consent and assent forms and the study questionnaire by mail. Patients 
visiting the DBAR at FIMR signed consent in person. Participants completed a short 
questionnaire about treatment details and symptoms. Data on clinical history, pubertal stage, 
anthropometrics and mid-parental heights were recorded. A broad age range was included 
due to the rarity of the disease. Serum ferritin and endocrine test results were collected and 
compared with age-appropriate reference standards (Table 1). If indicated, local endocrine 
evaluation was recommended.
Clinical and anthropometric data
Self-reported height and weight data were collected. Body surface area was calculated [16]. 
Height and weight SD scores were calculated based on Centers for Disease Control (CDC) 
2000 standards. Short stature was defined as height SD below −2.0 for age and gender. 
Parental heights were used to calculate MPH. BMI was calculated to the nearest 0.1 kg/m2. 
For patients under 18 years, BMI was compared to age and gender specific CDC 2000 
standards [17]. Adults were classified as normal BMI, overweight (BMI 25–29.9 kg/m2) or 
obese (BMI ≥30 kg/m2).
Patients > 8 years were assessed for pubertal development using tanner staging based on 
physical examination within the past year, or based on parent-assessed pubertal development 
(breast development in girls; genital enlargement and body hair in boys). Adult patients were 
asked if they had received hormone therapy to induce growth or puberty. Puberty was 
considered delayed if boys had no signs of pubertal maturation by age 14, or girls had no 
breast development by age 13.
Biochemical testing
Laboratory testing was systematically performed between 0700–0800 h after an overnight 
fast, prior to a blood transfusion and over two days for subjects under 10 years or weighing 
<65 lbs. FSH and LH were measured by immunochromatographic membrane assay (ICMA), 
steroid hormones by liquid chromatography followed by tandem mass spectrometry (LC-
MS/MS)[18,19].
Glucocorticoid-treated patients were presumed to have secondary adrenal insufficiency, 
unless adequate cortisol response to standard dose cosyntropin, (ACTH 1-24) was 
documented. Cosyntropin stimulation tests were performed in subjects with a screening 8 
AM cortisol < 16 micrograms/dl[20]. Adrenal insufficiency was classified as symptomatic or 
subclinical. Symptomatic adrenal insufficiency was characterized by a subnormal 60 minute 
cortisol response following cosyntropin with symptoms of fatigue, hypoglycemia, 
hyponatremia, or hyperkalemia. Subclinical adrenal insufficiency was characterized by 
biochemical evidence of adrenal insufficiency without symptoms[21] (i.e. 8AM cortisol <5 
Lahoti et al. Page 3
Pediatr Blood Cancer. Author manuscript; available in PMC 2016 April 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
micrograms/dL and/or inadequate cortisol rise to stimulation (peak <16 micrograms/dL)
[21]. Mineralocorticoid production was assessed based on published standards for 
aldosterone: PRA ratio[22].
GH deficiency was defined by peak level <10 ng/mL in response to two drug stimuli 
(arginine + clonidine or glucagon) [23].
The standard calcium - iPTH nomogram was used to interpret parathyroid gland 
function[24]. Serum 25(OH)D levels were interpreted as sufficient (>30 ng/mL), insufficient 
(20–30 ng/mL), or deficient (<20 ng/mL)[25].
Statistical analysis
Results were expressed as median (range) or mean ± 1 SD for continuous variables and 
frequencies for categorical variables. ANOVA was used to test the difference between means 
of two (t-test) or more groups, and Wilcoxon-signed rank test was used to test the difference 
between non-parametric variables. P<0.05 was considered statistically significant. Analyses 
were performed using JMP IN 7 software (SAS Institute, Cary, NC).
RESULTS
Patient characteristics (Tables II and III)
Fifty-seven patients were included, 38 of whom were transfusion-dependent whereas 19 
were non-transfusion dependent (seven in remission; 12 glucocorticoid-dependent. (Table 
II). Of the total 679 patients in the DBA Registry, 450 patients were eligible. Ninety-two 
patients were randomly selected and contacted for recruitment in the prospective study. Of 
these 45 patients consented and completed study participation (10% of those eligible). An 
attempt was made to obtain complete hormonal profile for all recruited patients; however for 
a number of patients for whom data was available in each sub-group was variable for 
different endocrine functions (see Table III). All percentages are expressed as a fraction of 
the patients with available data and refer to the entire cohort unless otherwise indicated.
Endocrine testing
Adrenal cortical function—Adrenal insufficiency as defined by the above criteria was 
present in 32% of patients (symptomatic: n=2, both transfusion dependent; sub-clinical: 
n=14, one patient receiving glucocorticoids and transfusions, one in remission and 12 
receiving glucocorticoids). Median prednisone dose for the glucocorticoid-dependent 
patients was 3.8 mg/m2/day (range 1.4–15.2). The median hydrocortisone equivalent dose 
(calculated using a 1:5 conversion factor) was 18.8 mg/m2/day (range 7–75.8). An 
additional 40% (n=20) had low cortisol levels suggestive of adrenal insufficiency, however 
confirmatory ACTH stimulation tests were not performed. Of these, 16 patients had 
relatively low AM cortisol levels (range: 6.2–12.6 micrograms/dL). Four patients, all 
transfusion dependent, had an absolutely low morning cortisol level (<5 micrograms/dL)].
Although 25% of the patients reported salt craving and/or dizziness, none were found to 
have mineralocorticoid deficiency. Adrenal androgens (DHEAS and/or androstenedione) 
were low for age and pubertal stage in 12% of patients (n=4). This included one patient in 
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remission; the remainder were transfusion dependent. Of the transfused patients, two were 
pubertal (age 15.7 years, tanner IV and age 20 years, tanner V) and had normal AM cortisol 
level, while the third had no signs of puberty (age 15 years) and a low AM cortisol.
Anterior pituitary function
Seven percent of patients (n=3) had received recombinant human growth hormone (rhGH); 
all were male and transfusion-dependent. Two of these patients were treated for GH 
deficiency (final height −1.3 SD and −2.3 SD; MPH −0.2 SD for both). The third patient had 
normal GH level, but low IGF-1 (<−3 SD for age), short stature (height −2.7 SD) and poor 
growth velocity; he was treated for presumed GH resistance. His final height was −3 SD 
(poor treatment adherence; MPH −1.3 SD). Additionally, 16% of patients (n=7) had low 
IGF-1 or IGFBP-3 levels.
Height SD was available for 33 patients, of whom 10 had a height <−2 SD (6 transfusion-
dependent, 2 glucocorticoid-dependent, 2 in remission). Both patient and mid-parental 
height SD values were available for 28 patients. Of these, 64% had a height SD of −1 below 
their MPH.
BMI could be calculated for 31 patients. Of these, 10% were underweight (n=3), 29% 
overweight (n=9) and 19% obese (n=6). The relative proportion of overweight and obese 
individuals was highest in the transfusion-dependent patients.
Posterior pituitary function
Diabetes insipidus (DI) was diagnosed in a single 16.5-year-old transfusion-dependent 
patient.
Glycemic control
The diagnosis of diabetes mellitus was made in one 14.5-year-old transfusion-dependent 
patient who presented with symptoms of hyperglycemia. Screening fructosamine levels, 
when available, were normal in all other patients.
Thyroid function
Hypothyroidism was reported in 14% of the patients (n=8, all transfusion-dependent). Four 
additional patients had mildly elevated TSH (range: 4.98–9.36 μIu/ml) and normal T4 ; and 
one asymptomatic glucocorticoid-dependent patient had a low free T4 with a low-normal 
TSH. Calcium metabolism, parathyroid function and Vitamin D.
Two patients had probable hypoparathyroidism (low calcium with inappropriately normal 
iPTH level), though none reported symptoms of hypocalcemia. One patient taking calcium 
supplements was hypercalcemic with a normal iPTH level. Approximately 28% of patients 
were taking supplemental vitamin D. Overall, 33% of patients (n=17) had insufficient 
25(OH)D levels; 24% (n=12) were vitamin D deficient including some on supplemental 
vitamin D. Though data was not prospectively collected for urine calcium excretion, 
hypercalciuria (elevated spot or 24 hour urine calcium: creatinine ratio) and/or kidney stones 
were reported by 7% of the patients (n=4, ages 11.6–30.3 years, while three of these were 
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transfusion-dependent and receiving chelation with deferasirox, the fourth patient was 
receiving both glucocorticoids and transfusions and chelation with deferoxamine). Vitamin 
25(OH)D levels on these patients were in the low-normal range; three had a family history 
of kidney stones.
Data for bone density was not prospectively collected, however osteoporosis was reported in 
4 patients: three adults (aged 27–34.9; 2 males, 1 female) and one male child (age 11.6), all 
transfusion-dependent. [26] All had BMD ≤ −2 SD. The child also had multiple vertebral 
compression fractures (children diagnosed based on most recent densitometry guidelines 
[26]). Three additional patients had adverse skeletal outcomes that developed during 
glucocorticoid therapy (ages 10.4–20, including a hairline leg fracture and avascular necrosis 
of the femoral neck). Osteopenia was reported in another 2 patients: a 19-year-old 
glucocorticoid-dependent female and 21-year-old male treated with glucocorticoids and 
transfusions.
Gonadal function
Among children >8 years and adults, hypogonadism was present in 29% of patients (n=10), 
three of whom were not previously diagnosed. All were diagnosed at ≥ 14.4 years of age and 
were transfusion-dependent. The male to female ratio was 8:2 (diagnosed at or after 14.4 
years). Considering age cut-offs for delayed puberty (Table 1), 47% of males >14 years had 
hypogonadism, while only 15% of females >13 years had hypogonadism. None of the 
patients attempted pregnancy during the study.
Iron overload
Ferritin levels were available for 46 patients, 80% of which (n=37) were above respective 
reference ranges [median 1141 ng/mL (range 214 – 5993)]. Of these 37 patients, most were 
chronically transfused, four were glucocorticoid-dependent and one was in remission. The 
ferritin level for the glucocorticoid dependent patients ranged from 330 – 689 ng/mL (last 
transfused 11 months to 7 years prior to this study). The ferritin level for the patient in 
remission was 1993 ng/mL (last transfusion 30 years earlier). On further investigation this 
patient was found to be homozygous for the C282Y mutation in the HFE gene, indicating 
primary hemochromatosis. There were insufficient liver iron concentration data by MRI to 
quantitate iron burden. Therefore, statistical analysis of the relationship between iron burden 
and endocrine abnormalities could not be performed.
DISCUSSION
Our report evaluates endocrine function in patients with DBA treated with transfusions or 
glucocorticoids and those in remission. We found a considerably higher incidence of 
endocrinopathies than previously reported. In our cohort, 53% of patients had one or more 
endocrinopathies (not including vitamin D deficiency/insufficiency). In order of frequency, 
these included adrenal insufficiency, hypogonadism, hypothyroidism, growth hormone 
deficiency/resistance, diabetes mellitus and diabetes insipidus (Figure 1).
Osteoporosis/osteopenia and hypercalciuria were also reported by history, although primary 
data were not uniformly available. Published reports from European DBA registries have 
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focused primarily on chronically transfused patients[9–13]. In the Italian cohort, 23% of 
patients (7 of 31, median age 9.2 years, range 1.8–29.6) had one or more iron-related 
endocrine or other organ complications. In the French cohort, ~14% of patients (13 of 95, 
mean age 13.5 ± 10.4 years) had endocrinopathies; few iron overloaded transfused patients 
were tested. In both reports, hypothyroidism was most frequent, followed by 
hypogonadism[12,13]. Amongst our chronically transfused patients, 45% (17 of 38) had one 
or more endocrinopathies, likely due to their older age (median age 17.4 years, range 2.3–
43), and because screening was done irrespective of symptoms or degree of iron overload.
In our study, patients underwent their first endocrine evaluation anywhere from 1.5 to 30.6 
years after DBA diagnosis, with glucocorticoid-dependent patients among the earliest 
evaluated. The median interval from diagnosis to first endocrine evaluation was 3.5 years for 
those patients who were corticosteroid-dependent, 4.5 years for those in remission, and 8.3 
years for transfusion-dependent patients. This is noteworthy, as high transfusion burden was 
most often associated with endocrinopathies. Approximately 33% of all patients indicated 
that they had never undergone a prior endocrine evaluation. While the age at diagnosis of 
pre-existing endocrinopathies was not uniformly captured in our study, for the few patients 
that this information was available, the age at diagnosis of a first endocrinopathy ranged 
from 13.5–19 years. This does not include glucocorticoid-dependent patients with presumed 
iatrogenic adrenal insufficiency.
Adrenal insufficiency was the most common endocrinopathy in our cohort: 32%, including 
all glucocorticoid-dependent patients who were presumed to have secondary adrenal 
insufficiency by the virtue of treatment with prolonged or supraphysiologic doses. Although 
less common, sub-normal cortisol response was also seen in patients receiving transfusions 
(9%) or in remission (20%). The etiology of adrenal insufficiency in the latter groups was 
unclear; we postulate that this may be related to prior transfusions. In comparison, 
subclinical adrenal insufficiency has been reported in 13–46% of beta-thalassemia 
patients[27,28]. Sources of variability include the test methodology and cortisol cut-off used.
Hypogonadism in patients >8 years age was the second most common endocrinopathy in our 
cohort (29%; M:F ratio =3:1), all from the transfusion-dependent group. Clinical 
presentations included failure to initiate puberty, arrest of puberty, and loss of libido or 
sexual function after puberty. Prior studies in patients with DBA have reported a 
hypogonadism prevalence of 8–13%, somewhat lower than our study[12,13]. The reported 
prevalence in beta-thalassemia patients ranges from 32–55%, increasing with age[5,29,30]. 
Pituitary iron overload in transfusion dependent patients with thalassemia and DBA can 
begin in the first decade of life, but clinically significant pituitary volume loss occursin the 
second decade[31]. At least half the patients with hypogonadism in our cohort had central 
hypogonadism, suggesting pituitary or hypothalamic iron overload.
Hypothyroidism has been previously reported in 3% and 16 % of patients with DBA in the 
Italian and French cohorts, respectively[12,13]. This is similar to our findings of 14% in our 
whole cohort and 22% of transfused patients. In comparison, prevalence of hypothyroidism 
in the beta-thalassemia population was found to be 8.7% (range 0–18%)[5], depending on 
the number and age of subjects.
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Of our patients with available height measurements, 30% had short stature, similar to that 
reported from the French DBA registry[12] and to the 25–31% for patients with beta-
thalassemia[5,29]. Of our patients, 60% had heights > 1 SD below MPH. Short stature in 
DBA patients may be associated with skeletal malformations, type of treatment and iron 
overload status[12,32]. Data on skeletal malformations were not collected in our study. 
Three patients in our study received rhGH therapy. There have been reports of positive 
outcomes using growth hormone for both growth hormone deficiency and resistance in 
patients with DBA [11,12,33]. A recently published retrospective report on rhGH therapy in 
patients with DBA showed significant increases in height velocity up to two years and height 
Z-scores up to four years after starting GH therapy. Adult heights were not obtained. Of 
note, in this study, the baseline peak stimulated GH level for the treated patients was 
11.5±10.6 ng/mL indicating that only some were GH deficient based on the most liberal cut-
off of 10 ng/mL[34]. The association of DBA and various malignancies, especially 
osteosarcoma[15,35], raises theoretical concerns about GH safety that must be explained to 
the patient and family. GH treatment should be monitored by maintaining serum IGF1 in the 
mid-normal range for age.
Vitamin D insufficiency and deficiency were common in our cohort, with 57% having a 
25(OH)D level below 30 ng/mL (75 nmol/L), despite some taking supplements. This 
proportion is somewhat lower than estimates in the general population and beta-thalassemia 
patients[5,36]. These findings suggest that either supplemental doses of vitamin D were 
inadequate or that patients were not adherent to the prescribed regimen. Chronic transfusions 
and associated co-morbidities are known risk factors for fractures, reported in up to 36% of 
patients with thalassemia[37]. Osteopenia, osteoporosis and/or fragility fractures were 
reported in a minority of our patients (n=9), though the information was based on self-report 
only and bone density data were not uniformly available. Hypercalciuria, nephrocalcinosis 
and/or kidney stones were present in 4 patients. Among the risk factors for nephrolithiasis 
were treatment with deferasirox[38] and a family history of kidney stones. Although 
hypercalciuria has been described in up to 21% of patients with beta-thalassemia, perhaps 
due to deferasirox [5,38], this was a new finding in patients with DBA.
While diabetes mellitus developed in only one transfusion-dependent patient at age 14.5, it 
has been described in both transfusion-dependent and glucocorticoid-dependent 
patients[13,14]. It appears to be less frequent in DBA than in beta-thalassemia (14.1%)[5]. 
The best screening test for diabetes in transfusion-dependent patients is controversial. One 
recent study in thalassemia patients found continuous glucose monitoring promising[39].
One patient with panhypopituitarism due to iron overload developed diabetes insipidus, 
another finding not previously reported in DBA. Symptomatic hypoparathyroidism was not 
diagnosed, although it was suspected in two patients and has been described[12,13].
Ferritin is not a reliable marker of iron burden or the chronicity of iron overload. Hence, 
statistical correlation between iron burden and the presence of endocrinopathies was not 
performed.
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Intrinsic limitations of our study include the small population due to the rarity of DBA, the 
cross-sectional nature of data collection, and geographic distance from the study center for 
the majority of DBAR patients. Other limitations were the relative young median age of our 
patients, self-reported parental heights, growth measurements and pubertal stage for several 
patients, assays done in different laboratories and the lack of data on hepatic and cardiac 
MRIs as measures of iron burden. Due to the small number of patients in remission, the 
study was not adequately powered to exclude a contributing effect of DBA itself on any of 
the endocrine diagnoses. Despite these limitations, this study is unique in that it evaluated 
endocrine dysfunction in a large DBA cohort, both children and adults, regardless of mode 
of treatment, and has thus improved our knowledge in this field.
In summary, over half of the studied DBA patients (53%) had one or more endocrinopathies, 
several beginning in childhood. While most of these were present in transfused patients, 
glucocorticoid-dependent patients and those in remission also showed endocrine 
dysfunction. Based on our experience, we make the following suggestions regarding 
endocrine screening of DBA patients:
1. Graphing height and weight should be done in children and adolescents every 6–12 
months to timely diagnose growth failure. BMI should also be monitored.
2. Screening for gonadal insufficiency should be considered in all transfused patients 
with delayed puberty, cessation of pubertal progression, or loss of libido or sexual 
function in adults.
3. Hypothyroidism screening should be considered in all DBA patients irrespective of 
treatment type or remission state after age 14.
4. Periodic screening by early morning serum cortisol measurement is suggested in 
iron overloaded patients, and cosyntropin testing in patients after discontinuation of 
glucocorticoids to ensure normal adrenal function.
5. Vitamin D supplementation should be given to maintain 25(OH)D levels above 30 
ng/mL (75 nmol/L). Consider screening urine calcium:creatinine ratio annually for 
hypercalciuria. Periodic bone density measurements should begin in late childhood.
6. Annual screening for diabetes mellitus should begin by age 14. HbA1c may be used 
to screen non-transfused patients, with fructosamine or oral glucose tolerance test 
in transfused patients. Screening for diabetes insipidus should also be considered in 
symptomatic patients.
7. Since prevalence of endocrinopathies tends to increase with age, normal screening 
labs at any age should not preclude lifetime monitoring of these patients. Timely 
diagnosis and treatment may serve to avoid further morbidities.
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DBA Diamond Blackfan Anemia
DBAR Diamond Blackfan Anemia Registry
SD Standard deviation
IGF-1 Insulin-like growth factor 1
IGFBP-3 Insulin-like growth factor binding protein 3
TSH Thyroid stimulating hormone
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Figure 1. Endocrine dysfunction in patients with Diamond Blackfan Anemia
Bar diagram showing frequencies of various endocrine dysfunction in our patients with 
Diamond Blackfan anemia
* This includes all patients with 25(OH)D levels <20 ng/mL and 20–30 ng/mL
** Most of these patients were receiving chronic glucocorticoid therapy and had presumed 
secondary adrenal insufficiency.
*** Other endocrinopathies including diabetes mellitus, diabetes insipidus, osteoporosis, 
osteopenia and hypercalciuria were present in a minority of patients
#Total number of patients evaluated for each endocrinopathy somewhat varied as detailed in 
Table III.
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Table I
Test results collected for evaluation of function of various endocrine glands
Endocrine gland Tests
Anterior pituitary gland* insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), prolactin
Posterior pituitary gland serum and urine osmolality
Thyroid gland thyroid stimulating hormone (TSH), total and free T4
Parathyroid gland and vitamin D metabolism calcium, intact parathyroid hormone (iPTH), 25-OH-vitamin D [25(OH)D]
Adrenal cortex: glucocorticoid synthesis AM Cortisol
Adrenal cortex: mineralocorticoid synthesis plasma renin activity (PRA), aldosterone
Adrenal cortex: sex steroid synthesis androstenedione, dehydroepiandrosterone sulphate (DHEAS)
Pancreatic endocrine function/glucose metabolism** fructosamine (or HbAlc in non-transfused patients)
Gonadal function for ages ≥ 8 years# luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone and sex 
hormone binding globulin (SHBG) (in males); and estradiol (in females).
*Additional tests for evaluation of other pituitary hormones are mentioned along with the respective endocrine glands they regulate.
**
HbA1c value >6.5% as per ADA guidelines used to screen for diabetes mellitus in non-transfused patients, but not: as reliable in patients 
transfused frequently. Fasting and post-prandial glucose can provide a good measure of glycemic control in transfused patients, but was not feasible 
to obtain due to the design of study. Fructosamine used as a screen for short-term glycemic control and some studies show correlation between 
fasting glucose and fructosamine level. However no definitive fructosamine level is considered diagnostic for diabetes and patients with values 
outside laboratory reference range need further evaluation.
#
Patients on sex hormone replacement with a history of delayed puberty (defined as no breast development in girls >13 years and no testicular 
enlargement in boys >14 years) are considered to have hypogonadism. Additionally, patients with elevated FSH and/or LH with or without low sex 
hormones are considered to have primary hypogonadism. Secondary hypogonadism diagnosed in patients with low LH and/or FSH and sex 
hormones with evidence of other pituitary hormone deficiencies; those with history of hypogonadism and on treatment with human chorionic 
gonadotropins (HCG) or in males on long term androgen therapy for anemia.
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Table II
Patient Characteristics
Parameter Overall On Chronic Transfusions Glucocorticoid-dependent Remission*
n 57 38 12 7
Age (in years) at endocrine 
evaluation€
14.4 (2–43) 17.4 (2.2–43)§ 10.5 (2–30.7) 12.9 (3–33.2)
Males (%) 56 58 50 57
Height SDS#€ −1.1 (−3.2 to 1.7) −1.1 (−3.2 to 0.1) −1.3 (−2.4 to 0.4) −0.6 (−2.6 to 1.7)
Difference between subject’s height 
SDS and MPH height SDS€¥
−1.2 (−4.6 to 0.6) −1.2 (−4.6 to 0.3) −0.6 (−2.3 to 0.6) −1.2 (−1.6 to −1.0)
€
Expressed as Median (range).
§
< 0.05 for DBA transfused group versus glucocorticoid-dependent group.
*
Duration of remission >2 years (range 2–28 years) in all subjects except for 1 patient (6 months).
#
Height SDS data available for 33 DBA patients (n=19, 10 and 4 respectively in chronic transfusion, glucocorticoid-dependent and remission 
groups).
¥
Both patient and mid parental height SDS data were available for 28 DBA patients (n=19, 5 and 4 respectively in chronic transfusion, 
glucocorticoid-dependent and remission groups).
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Table III
Table showing frequencies of various endocrinopathies in patients with Diamond Blackfan anemia
Overall* On chronic Transfusions* Glucocorticoid-dependent* Remission*
Patients with endocrinopathies
a) None
b) One only
c) Two only
d) Three only
e) Greater than
three
f) Indeterminate screening labs
a) 30% (17/57)
b) 37% (21/57)
c) 10% (6/57)
d) 4% (2/57)
e) 2% (1/57)
f) 17% (10/57)
a) 34% (13/38)
b) 26% (10/38)
c) 11% (4/38)
d) 5% (2/38)
e) 3% (l/38)
f) 21% (8/38)
a) 0/12
b) 83% (10/12)
c) 17% (2/12)
d) 0/12
e) 0/12
f) 0/12
a) 57% (4/7)
b) 14% (l/7)
c) 0/7
d) 0/7
e) 0/7
f) 29%(2/7)
Adrenal insufficiency (for glucocorticoids)
a) Symptomatic
b) Subclinical
a) 4% (2/50)
b) 28% (14/50)
a) 6% (2/33)
b) 3% (1/33)
a) 0/12
b) 100% (12/12)
a) 0/5
b) 20% (1/5)
Mineralocorticoid insufficiency 0/30 0/19 0/8 0/3
Adrenal Sex steroid insufficiency 12% (4/32) 12% (3/24) 0/5 33% (1/3)
Growth hormone dysfunction 7% (3/45) 10% (3/30) 0/10 0/5
Diabetes insipidus 2% (1/39) 4% (1/27) 0/9 0/3
Hypothyroidism 14% (8/55) 22% (8/36) 0/12 0/7
Diabetes mellitus 2% (1/40) 4% (1/28) 0/9 0/3
Ca-iPTH abnormalities
a) Probable Hypoparathyroid ism
b) Hypercalcemia with normal iPTH
a) 4% (2/46)
b) 2% (1/46)
a) 3% (1/31)
b) 0/31
a) 10% (1/10)
b) 10% (1/10)
a) 0/5
b) 0/5
Vitamin D
a) insufficiency
b) deficiency
a) 33% (17/51)
b) 24% (12/51)
a) 35% (12/34)
b) 26% (9/34)
a) 27% (3/11)
b) 9% (1/11)
a) 33% (2/6)
b) 33% (2/6)
Hypogonadism (among children >8 years 
and adults)
29% (10/34) 40% (10/25) 0/5 0/4
Iron overload 80% (37/46) 97% (32/33) 40% (4/10) 33% (1/3)
*
Data expressed as: Percentage of patients with the disorder (number of patients with the disorder/number of patients for whom data was available)
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